enablex 7.5mg prolonged release tablets prolonged-release tablet
novartis - darifenacin hydrobromide - prolonged-release tablet - 7.5 mg
enablex 7.5mg prolonged release tablets
aspen pharma trading limited (aptl), ireland - darifenacin hydrobromide - prolonged-release tablet - 7.5 mg
daritor-15
torrent pharmaceuticals - darifenacin hydrobromide - tablet, coated; oral - 15mg
daritor-7.5
torrent pharmaceuticals - darifenacin hydrobromide - tablet, coated; oral - 7.5mg
enablex 7,5 mg tablet
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains darifenacin hydrobromide equivalent to darifenacin 7,5 mg
enablex 15 mg tablet
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains darifenacin 15,0 mg
darif 10 tab
summit - darifenacin hbr - tab - 7.5mg - 10
darilong 5*10
sun - darifenacin hbr - 15mg - 5*10
darilong 5*10
sun - darifenacin hbr - 7.5mg - 5*10
itrazole
viatris limited - itraconazole 100mg; - capsule - 100 mg - active: itraconazole 100mg excipient: capsugel red g60csa00150 colloidal silicon dioxide ethanol gelatin hypromellose iron oxide red methylene chloride opacode white s-1-7078 purified water sorbitan stearate sugar spheres titanium dioxide - itraconazole capsules are indicated for the treatment of: · vulvovaginal candidiasis. · pityriasis versicolor, · dermatomycosis - including highly keratinised regions as in plantar tinea pedis and palmer tinea manus, · fungal keratitis, · oral candidiasis, · onychomycosis caused by dermatophytes and/or yeasts. · systemic mycoses, only in the following fungal infections: - systemic aspergillosis - histoplasmosis, - histoplasmosis, maintenance therapy only in aids patients - sporotrichosis (including lymphocutaneous/cutaneous and extracutaneous) - paraconccidioidomycosis, - chromomycosis, - blastomycosis